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Background: SLC6A8, an X-linked gene, encodes the creatine transporter (CRTR) and its mutations lead to cerebral
creatine (Cr) deficiency which results in mental retardation, speech and language delay, autistic-like behaviour and
epilepsy (CRTR-D, OMIM 300352). CRTR-D represents the most frequent Cr metabolism disorder but, differently from
Cr synthesis defects, that are partially reversible by oral Cr supplementation, does not respond to Cr treatment even
if precociously administrated. The precursors of Cr are the non-essential amino acids Glycine (Gly) and Arginine
(Arg), which have their own transporters at the brain–blood barrier level and, therefore, their supplementation
appears an attractive and feasible therapeutic option aimed at stimulating Cr endogenous synthesis and, in this
way, at overcoming the block of Cr transport within the brain. However, until now the effects of Arg and/or Gly
supplementation on Cr brain levels and behaviour have been controversial.
Methods: In this study five Italian male patients affected by CRTR-D were supplemented with oral L-Arg at a
dosage of 300 mg/kg/day divided into 3 doses, for 24–36 months. Biochemical and plasmatic amino acids
examinations and thyroid hormone dosages were periodically performed. Moreover, Proton and Phosphorus
Magnetic Resonance Spectroscopy (MRS) was monitored during follow-up in concurrence with neuropsychological
evaluations.
Results: During L-Arg treatment a clinical improvement in motor skills and to a lesser extent in communication
and attention was observed. In addition, all patients had a reduction in the number and frequency of epileptic
seizures. Daily living skills appeared also to be positively influenced by L-Arg treatment. Moreover, Total Cr and
especially PhosphoCr, evaluated by proton and phosphorus spectroscopy, showed a mild increase, although well
below the normal range.
Conclusion: This study provides information to support the effectiveness of L-Arg supplement treatment in CTRT-D
patients; in fact the syndromic pattern of cognitive and linguistic deficit presented by CRTR-D patients was partially
altered by L-Arg supplementation especially at a qualitative clinical level. Oral L-Arg may represent not only a
protective factor towards a further cognitive decline, but can lead to the acquisition of new skills.
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Creatine Transporter Deficiency (CRTR-D) (MIM#300036)
is a X-linked disorder caused by SLC6A8 gene mutation
and represents the most frequent disorder of Creatine (Cr)
metabolism [1-3] and one of the causes of X-linked mental
retardation (XLMR) in a percentage varying from 2.1% to
3.5% in a European XLMR panel [4,5].
CRTR-D is characterized by mental retardation of vari-
able degree, language deficit, behavioural disorders, epilepsy
[6-13], cardiac manifestations [11] and gastrointestinal pro-
blems in adult patients [12]. Since first described in 2001
[6], more than 150 patients from 60 families and more thanTable 1 Clinical and laboratory findings of the study sample
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Differently from Cr synthesis defects, where clinical symp-
toms may be partially reversed by oral Cr supplementation
(AGAT deficiency, OMIM 602360) [19,20] or plus a regimen
aimed at reducing Guanidino Acetate (GAA) accumulation
(GAMT deficiency, OMIM 601240) [2,21,22], Cr supple-
mentation resulted ineffective for CRTR-D [2,3,7,23,24], also
when precociously provided [12]. Supplementation with L-
arginine (L-Arg) alone [25,26] or in combination with Cr
and/or L-glycine (L-Gly) has been described, although its ef-
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logical profile of patients affected by CRTR-D [8], in par-
ticular in terms of neuropsychological standardization
tests [10,18,25,26,28,29]; the even fewer studies on adult
patients, confirm the presence of mental retardation
[11,30] or deterioration [12].
In this study we have investigated five Italian CTRT-D
children in order to describe: a) their neuropsychological
profile b) the effects of L-Arg supplementation on im-
proving intellectual and behavioral disorders.
Material and methods
Patients
Five Italian male children with genetically confirmed
CRTR-D diagnosed at IRCCS Stella Maris, Pisa (P1, P2)
and IRCCS Gaslini, Genoa (P3, P4, P5) and regularly
monitored at these two respective Children Hospitals
were recruited for this study.
The diagnosis was suspected on the basis of an
increased urine Cr/Creatinine ratio and further con-
firmed by the absence of Cr peak at proton magnetic
resonance spectroscopy (1H-MRS) and by SLC6A8 gene
examination. The pathogenetic role of the mutation was
confirmed by the assessment of Cr uptake in fibroblasts
or lymphoblasts. Clinical, laboratory and magnetic res-
onance findings had already been reported in previous
publications on four patients [9,10,15,18].
The clinical and laboratory data are summarized in
Table 1.
The study was approved by the Ethical Committee of
the IRCCS Stella Maris. Informed participation consent
was obtained from all parents.
Treatment and biochemical and spectroscopy monitoring
All patients were supplemented with oral precursor of Cr,
L-Arg, at a dosage of 300 mg/kg/day divided into 3 doses,
for 24 and 36 months. The rationale for the choice of
L-Arg therapeutic trial was based on several considera-
tions: i) Arg acts as substrate stimulating the synthesis of
Cr at level of astroglial cells [31] and peripheral cells [32];
ii) every brain cell is able to uptake Arg [33,34], so ensur-
ing its own local needs in Arg for Cr synthesis or other
metabolic requests; iii) in comparison with Gly, clinical
pharmacology of Arg is relatively well known in term of
efficacy, dosages, routes of administration, and side effects
in adults and children [35] and thus we ruled out the pos-
sibility to administer both precursors (Gly and Arg) in
order to avoid possible confounding results. Finally we
were discouraged from adding oral Cr supplementation
considering the extremely low residual Cr transport we
detected in the fibroblasts from our patient [10].
Blood and urine amino acids, ammonia, urea nitrogen,
blood Cr and creatinine, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), creatine kinase (CK),lactate dehydrogenase (LDH), amylase, TSH, T3, T4, blood
cell count and haemoglobin were periodically monitored
in all patients. Moreover, brain Cr and Phosphocreatine
(PCr) fluctuations under treatment were monitored re-
spectively by means of Proton and Phosphorus MRS
which were performed before (P1, P2, P3) and during Arg
supplementation (P1, P2, P3, P4, P5), contemporarily with
neuropsychological examinations. P4 and P5, followed to
IRCCS Gaslini, were included in the study after two and
one year of treatment respectively.
At Proton MRS total brain Cr (tCr) was measured in
terms of absolute concentration, expressed in mmol/liter
VOI (mM), using the LCModel. Phosphorus MRS was ana-
lyzed with a Spectra data processing software (SAGE/IDL)
and PosphoCreatine (PCr) was measured in terms of ratio
with respect to the phosphodiester signal (PDE) that was
chosen as an internal reference since this metabolite is not
included in any known metabolic circuit in cellular ATP
production [25,36].
Neuropsychological assessment
The children were submitted to a comprehensive neuro-
psychological evaluation, in particular: cognitive abilities
were assessed by means of Griffiths Scales [37], an index of
non-verbal intelligence derived from the combination of
scores from the scales for Eye-Hand Coordination and Per-
formance, while language evaluation included: productive
vocabulary (the Italian version of the Mac Arthur-Bates
Communication Development Inventories for Infants and
Toddlers - CDI), Axia Vocabulary Test and receptive vo-
cabulary (Peabody Picture Vocabulary Test, PPVT), sen-
tence comprehension (Test of Comprehension of Grammar
for children, TCGB), level of language organization in spon-
taneous speech and in sentence repetition test (see ref. 10
for a more detailed description and references of language
assessment). Adaptive functioning in motor, communica-
tion daily living and socialization domains was also evalu-
ated using the Vineland Adaptive Behaviour Scales (VABS).
Since not all patients were able to cooperate in the struc-
tured tests at baseline (T0), we reported their data from
the first neuropsychological assessment during L-Arg treat-
ment where cooperation was obtained. Neuropsychological
evaluation was then repeated every year from T0, i.e. the
beginning of treatment (T1= 12 months, T2=24 months,
T3=36 months). VABS data were instead available starting
from T0 to follow-up study for all patients.
Results
Clinical data
During L-Arg treatment, we observed clinical improvement
involving motor skills with acquisition of better dynamic
coordination and only relative progress in communication
and attention. Furthermore, there was a reduction in the
number and frequency of epileptic seizures in all patients;
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therapy with monotherapy, in P1 the antiepileptic drug ad-
ministration was stopped and in P3 a mild electroclinical
improvement was observed, although he had not been
administered antiepileptic drugs for a long time by decision
of the family.
No important side effects were observed in any
patients during oral L-Arg supplementation with the ex-
ception of incidental episodes of diarrhea, mainly related
to adaptation to L-Arg dosage. An increase of body
weight during the treatment was noticed only in P1
while all patients showed an increase of muscular
strength without clinical change of muscle mass.
During treatment total brain Cr (tCr) and, especially,
phosphocreatine (PCr) showed a mild increase, more
evident during the first months of Arg treatment and
then remained quite stable throughout the other exami-
nations, although well below the normal range (Table 1,
line MRS) [25,36].
Neuropsychological profile at basal time and during
follow up
The Griffiths Scales revealed different degrees of intel-
lectual disability varying from mild (P2) to moderate
(P1, P4) and to severe (P5). In all patients the profiles
were characterized by a significant discrepancy between
non-verbal and verbal skills with lower scores in Hearing
& Speech and Practical reasoning scales and better
scores in Eye-Hand coordination and Performance
Scales. Due to the severe cognitive impairment with
autistic-like behaviour of patient P3 a systematic neuro-
psychological assessment was not possible; however, se-
vere degree of cognitive impairment was apparent from
spontaneous observation. A stability in all subscales was
observed, at least during the three years of our follow
up.
In Figure 1 we reported the modifications on Griffiths
scale of three patients (P2, P4, P5) during treatment. P1
data had been already reported [25].
The neuropsychological profile of the patients (with
the exception of P3) is reported in Figure 2. In order to
compare the performance of different tests for each pa-
tient, the results were expressed in equivalent age (EA).
For all testable subjects the expressive language per-
formance appeared markedly reduced in comparison to
receptive lexicon and non-verbal abilities. Moreover
within verbal domain, sentence comprehension, even if
delayed, was more preserved with respect to expressive
language measures.
For all children the most affected area was expres-
sive language, even if this impairment was present in
differing degrees: P1, P4, P5 demonstrated productive
language limited to isolated words and simple com-
binatorial speech with some simple routine utterancesintegrated with some deictic, iconic and representative
gestures. Signs of oral-motor and speech dyspraxia
were also present, more prominent in P1 [10]. Lan-
guage skills were more advanced in P2: spontaneous
language was at the level of production of multiword
utterances mostly morphologically incomplete for
omission of free grammatical morphemes and errors
of bound morphology [18]. In P3 language was almost
absent with sporadic production of echolalic and non-
communicative speech.
During L-Arg treatment the four testable patients
experienced a transformation in language skills: in par-
ticular, it was interesting to note that after the first two
years of treatment P1, P2 and P5 showed an increment
in grammatical comprehension of 18 (P2, P5) and 27 EA
months (P1), while P4’s grammatical production
improved by more than 20 EA months. These data
appeared relevant also in comparison to the slow devel-
oping pace of children up to the beginning of the treat-
ment. Interestingly, L-Arg supplementation seemed
more effective in the verbal domain, particularly com-
promised in these patients, than in the cognitive non-
verbal domain.
Even if a regular neuropsychological assessment was
not obtained from P3, clinical observation revealed an
improvement in eye contact, motor hyperactivity, atten-
tion span, and repetitive behaviour.
As indicated in Figure 3, VABS showed, even if in vari-
ous degrees of difficulty, a similar profile concerning
adaptive skills in all patients. This profile was character-
ized by relatively better skills in daily living and motor
abilities scales and lower abilities in communication and
socialization, with the exception of P1 who showed a
socialization skills score just under daily living skills.
After L-Arg supplementation VABS profiles demon-
strated an improvement in adaptive skills in all patients,
more evident for motor skills, with the exception of P3.
In particular, P2 and P4 showed an increment of
20 months and 13 EA months respectively, greater than
expected in the lapsed period of one year, especially con-
sidering the previous pace of development. Daily living
skills also appeared to be positively influenced by L-Arg:
P1, P2 and P4 showed an increment of 24, 12 and
14 months respectively. On the contrary socialization
skills seemed to receive no or little advantage from the
L-Arg supplementation with the exception of P2 who
showed a 14 month improvement; likewise communica-
tion skills also demonstrated reduced advantages, with
the exception of P2 and P4 who showed a remarkable
improvement of 31 and 11 months respectively.
Discussion
The present study was designed to describe the pattern










































Figure 1 Modifications in Griffiths Scale of three patients (P2, P4, P5) during treatment. The results are expressed in equivalent age (EA).
T0 = baseline; T1, T2, T3: after 12, 24, 36 months of L-Arg supplementation, respectively.
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tioning during the treatment with L-Arg. Several factors
(SLC6A8 mutation, age at diagnosis and at start of sup-
plementation treatment, environment, co-morbidity and
compliance) could contribute to the complexity of the
CRTR-D clinical picture and in particular could influ-
ence the responsiveness to treatment.
Our CRTR-D patients’ profile appeared characterized
by language deficits with dyspraxia and/or severe expres-
sive language deficit with lexical receptive skills more
advanced with respect to their mental age. There was a
relative sparing of vocabulary comprehension in the
context of different degree of mental retardation.The first signs of the disease occurred in all patients in
the first year of life with psychomotor and language
delay, but the CRTR-D diagnosis always arrived later
(mean age at diagnosis 7.6 yrs). Developmental course
was characterized by a long phases of ‘development
stagnation’ resulting in very restricted expressive lan-
guage skills, cognitive and behavioural deficits, despite
early speech and psychomotor therapy.
Most CRTR-D patients of previously published series
[28,29] were described as affected by a pervasive devel-
opmental disorder (PDD) or PDD not otherwise speci-
fied (PDD-NOS) (i.e. they showed signs of autism
spectrum). Conversely, only one of our cases (P3)
P2
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Figure 2 Neuropsychological profiles of the four testable patients (P1, P2, P4, P5) during follow-up with oral arginine
supplementation. The results are expressed in equivalent age (EA). T0 = baseline; T1, T2, T3: after 12, 24, 36 months of L-Arg supplementation,
respectively.
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neuropsychological evaluation by standardized tests dif-
ficult, as in our patient. The clinical differences and the
difficulties in testing might partially account for the
somehow better response to treatment reported in our
studies.
Clinical variability between CRTR-D patients may be
due to their genetic abnormalities; in our series, two
patients (P1 and P5) showed the same mutation (Table 1)
and presented a more severe language phenotype than
the others. This same mutation was previously reported
by Clark [17] in a patient with Attention Deficit and
Hyperactivity Disorder (ADHD). One of our cases (P4)
showed the same mutation identified in other two cases
of Van de Kamp et al. [28] and in one case of Fons et al.
[26]. In these patients the clinical picture was mainly
characterized by mixed receptive-expressive language
disorder variously associated to moderate mental retard-
ation and epilepsy (P4), -PDD-NOS and ADHD [28],
and mild mental retardation [26].
Epileptic seizures represent an important feature of
CRTR-D patients relevant for the severity of their men-
tal disability. L-Arg supplementation could have a posi-
tive role on seizure treatment as described in our patient
(P3) and a more effective seizure control in association
with antiepileptic drugs (P1, P4, P5) [27].The decision to treat our children with oral L-Arg
supplementation was based on several considerations,
already discussed in the section of treatment and spec-
troscopy monitoring. L-Arg acts as substrate stimulating
the synthesis of Cr at the astroglia cell level and, because
every brain cell is able to uptake L-Arg [33], it is ensured
its own local needs of L-Arg for Cr or other metabolic
synthesis. Supplementation treatment with L-Arg alone
for only nine months was chosen by Fons et al. [26]
while in other studies a combination treatment with Cr,
L-Arg and L-Gly with various dosage and timing was
preferred [27-30]. The variable study protocols and the
clinical heterogeneity of the various reported cohorts,
especially for age at start of treatment, could explain the
different treatment responsiveness and CRTR-D
outcomes.
We found similar results for Proton and Phosphorus
MRS in all our studied patients: Cr and PCr peak
showed mild increase during Arg treatment (Table 1)
and, although these data are different from other
reported [28,29], worthy of attention and their signifi-
cance should be addressed in further future studies.
Moreover, we observed not only a relatively stable pat-
tern of neuropsychological functioning over time, but
also an improvement in adaptive skills, mainly in daily
living and in motor abilities. as possible cause of motor
Figure 3 VABS profiles in all five patients. After L-Arg supplementation there was an improvement in adaptive skills, more significant for
motor and daily living skills. The results are expressed in equivalent age (EA). T0 = baseline; T1, T2, T3: after 12, 24, 36 months of L-Arg
supplementation, respectively.
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velopmental Quotient scores were available from the
first year of life and before diagnosis; in these cases a de-
cline in scores was observed, conversely during L-Arg
supplementation a stability or slight improvement of
mental age was found.. An effect of repeated testing
could be reasonably excluded, since the intervals be-
tween evaluations were sufficiently long.
Also the subject institutionalized from the age of
10 years (P5) who had a late diagnosis (17 yrs), a severe
epilepsy and a greater decline of behavioural and intel-
lectual skills, showed a mobilization of the functional
profile after L-Arg supplementation, with improvement
especially in receptive language and motor and daily liv-
ing skills.Only patient P3 with severe epilepsy, not treated for a
long time by decision of the family, PDD-NOS and a
delayed start of L-Arg treatment (about 7 yrs after diag-
nosis) did not show any quantitative behavioural changes
after L-Arg supplementation.
The degree of behavioural change induced by L-Arg is
probably related to other variables, such as the presence
of varying degrees of drug-resistant epilepsy.
In Conclusion, this study provides information to sup-
port the validity of L-Arg supplementation treatment in
CTRT-D patients; in fact the syndromic pattern of cog-
nitive and linguistic deficit presented by CRTR-D
patients can be partially changed by L-Arg supplementa-
tion especially at a qualitative clinical level. Oral L-Arg
seems to represent not only a protective factor towards
Chilosi et al. Orphanet Journal of Rare Diseases 2012, 7:43 Page 8 of 9
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acquisition of new skills.
The course of this disorder seems thus to be partially
modifiable through the synergy of L-Arg treatment to-
gether with family compliance and administration of antie-
pileptic drugs, potentially making this syndrome a partially
treatable disorder, especially when diagnosis is precocious.
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